Pharmacogenetic considerations for late life depression therapy

Pothitos M. Pitychoutis, Nikolaos Kokras, Despina Sanoudou, Christina Dalla, Zeta Papadopoulou-Daifoti

Research output: Contribution to journalArticle

8 Citations (Scopus)


Introduction: Geriatric depression is a heterogeneous disorder with a complex genetic background. Current first-line treatment of depression is associated with a lower therapeutic outcome in aged depressed patients, when compared to younger subjects. Research which has explored this inadequate response has highlighted several factors which have come into play with the pharmacogenetics of antidepressants in the elderly being a particular area of interest. Areas covered: The authors perform a critical review of the English language articles from PubMed using search terms such as late-life/geriatric depression, antidepressants, pharmacogenetics, pharmacogenomics, pharmacokinetic, genetic, genotype, remission, therapy, treatment and polymorphism. Expert opinion: The emerging clinical and pharmacogenetic data are slowly unveiling the importance of the genome-age interaction in antidepressant response. This data introduces a critical new parameter in personalized medicine. A profound analysis of the age factor in the pharmacogenetics of antidepressant response is imperative, in order to elucidate the clinical significance of these findings and thereby improve patient treatment in the elderly.

Original languageEnglish
Pages (from-to)989-999
Number of pages11
JournalExpert Opinion on Drug Metabolism and Toxicology
Issue number8
Publication statusPublished - 1 Aug 2013
Externally publishedYes



  • 5-HTT gene-linked polymorphic region
  • Antidepressant drug
  • Brain-derived neurotrophic factor
  • Citalopram
  • Cytochrome P450
  • Dopamine transporter 1
  • Elderly
  • Geriatric depression
  • Remission
  • Serotonin transporter
  • Stressful life episodes
  • Treatment

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Pitychoutis, P. M., Kokras, N., Sanoudou, D., Dalla, C., & Papadopoulou-Daifoti, Z. (2013). Pharmacogenetic considerations for late life depression therapy. Expert Opinion on Drug Metabolism and Toxicology, 9(8), 989-999.